panitumumab,trifluridine,Tipiracil
amgen,taiho pharma
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'panitumumab']
panitumumab plus tas as anti-egfr rechallenge therapy in refractory ras wt #crc: os &amp; subgroup analysis of the randomized velo trial at #wcgic2023 rechallenge with anti-egfr seems to be effective pfs improved no os benefit, but 50% crossover 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology